Literature DB >> 28306557

MRI micturating urethrography for improved urethral delineation in prostate radiotherapy planning: a case study.

Robba Rai1, Mark Sidhom, Karen Lim, Lucy Ohanessian, Gary P Liney.   

Abstract

Stereotactic ablative body radiotherapy is used in prostate cancer to deliver a high dose of radiation to the tumour over a small number of treatments. This involves the simulation of the patient using both CT and MRI. Current practice is to insert an indwelling catheter (IDC) during CT to assist with visualisation of the urethra and subsequently minimise dose to this highly critical structure. However, this procedure is invasive and has an associated risk of infection. This is a case study, which demonstrates our initial experience of using a real-time non-invasive MRI technique to replace the use of IDC for prostate cancer patients. The patient was scanned on a dedicated 3T MRI and was instructed to micturate in their own time whereupon a sagittal T2 weighted HASTE sequence was acquired every 5 s. This was subsequently followed by T2 weighted axial imaging at the level of mid prostate to provide improved urethral definition. Acquired images showed bladder voidance in real-time and an increase in signal intensity in the proximal urethra post voiding allowing for delineation of the urethra. The dimension and shape of the proximal urethra was well visualised and accumulation time of urine in the urethra was sufficient to enable optimum timing of the scanning technique. We have presented for the first time a micturating urethography technique using MRI, which has allowed us to visualise the urethra without contrast and with minimal invasiveness to the patient.

Entities:  

Mesh:

Year:  2017        PMID: 28306557     DOI: 10.1088/1361-6560/62/8/3003

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  6 in total

1.  Comparison of Motion-Insensitive T2-Weighted MRI Pulse Sequences for Visualization of the Prostatic Urethra During MR Simulation.

Authors:  Kristen L Zakian; Andreas Wibmer; Hebert A Vargas; Eveline Alberts; Mo Kadbi; Borys Mychalczak; Marisa Kollmeier; Daniel Gorovets; Sean McBride; Margie Hunt; Michael J Zelefsky; Neelam Tyagi
Journal:  Pract Radiat Oncol       Date:  2019-06-25

Review 2.  Real-Time Magnetic Resonance Imaging.

Authors:  Krishna S Nayak; Yongwan Lim; Adrienne E Campbell-Washburn; Jennifer Steeden
Journal:  J Magn Reson Imaging       Date:  2020-12-09       Impact factor: 4.813

3.  First 500 Fractions Delivered with a Magnetic Resonance-guided Radiotherapy System: Initial Experience.

Authors:  Bilgehan Sahin; Teuta Zoto Mustafayev; Gorkem Gungor; Gokhan Aydin; Bulent Yapici; Banu Atalar; Enis Ozyar
Journal:  Cureus       Date:  2019-12-24

4.  A treatment planning study of urethra-sparing intensity-modulated proton therapy for localized prostate cancer.

Authors:  Takaaki Yoshimura; Kentaro Nishioka; Takayuki Hashimoto; Kazuya Seki; Shouki Kogame; Sodai Tanaka; Takahiro Kanehira; Masaya Tamura; Seishin Takao; Taeko Matsuura; Keiji Kobashi; Fumi Kato; Hidefumi Aoyama; Shinichi Shimizu
Journal:  Phys Imaging Radiat Oncol       Date:  2021-10-08

5.  Visualizing the urethra by magnetic resonance imaging without usage of a catheter for radiotherapy of prostate cancer.

Authors:  Takaaki Yoshimura; Kentaro Nishioka; Takayuki Hashimoto; Taro Fujiwara; Kinya Ishizaka; Hiroyuki Sugimori; Shoki Kogame; Kazuya Seki; Hiroshi Tamura; Sodai Tanaka; Yuto Matsuo; Yasuhiro Dekura; Fumi Kato; Hidefumi Aoyama; Shinichi Shimizu
Journal:  Phys Imaging Radiat Oncol       Date:  2021-03-26

6.  The urethral position may shift due to urethral catheter placement in the treatment planning for prostate radiation therapy.

Authors:  Yasuhiro Dekura; Kentaro Nishioka; Takayuki Hashimoto; Naoki Miyamoto; Ryusuke Suzuki; Takaaki Yoshimura; Ryuji Matsumoto; Takahiro Osawa; Takashige Abe; Yoichi M Ito; Nobuo Shinohara; Hiroki Shirato; Shinichi Shimizu
Journal:  Radiat Oncol       Date:  2019-12-12       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.